美国放射性皮肤炎市场规模、份额、趋势分析报告：按产品类型、分销管道、设施类型、细分市场预测，2024-2030 年

美国放射性皮肤炎市场成长与趋势：

Grand View Research最新报告显示，到2030年，美国放射性皮肤炎市场规模预计将达到4.8107亿美元，2024年至2030年复合年增长率为5.5%。

有几个重要因素促成了这种增长，包括癌症盛行率的增加、放射治疗技术的重大发展以及放射性皮肤炎新治疗方案的开发。癌症负担的增加是推动市场成长的关键因素。由于癌症是全世界死亡的主要原因之一，因此对有效放射线治疗和放射性皮肤炎的后续治疗的需求不断增长。经常需要放射线治疗的癌症类型（例如乳癌和摄护腺癌）的高发生率也有望支持市场扩张。此外，越来越多的老年人更容易罹患癌症等慢性疾病，这也推动了对放射性皮肤炎治疗的需求。

放射性皮肤炎新治疗方案的开拓，例如局部乳膏、敷料和口服药物，也有助于市场扩张。这些创新为患者提供了症状管理的选择，可能会提高生活品质并降低与严重放射性皮肤炎病例相关的医疗费用，但传统的放射性皮肤炎管理解决方案也可能减少需求。例如，2024年4月，Molnlycke宣布同意收购知名伤口清洗製造商PGF Industry Solutions GmbH。此次收购预计将巩固该公司作为创伤护理全球领导者的地位。

此外，医疗保健专业人员和患者对管理放射性皮肤炎重要性的认识和教育的提高也影响了成长。这种认知导致人们重视预防措施和早期疗育，这对于最大限度地减少放射性皮肤炎的严重程度和改善患者的治疗效果至关重要。医疗保健提供者、研发和製药公司之间的合作开发和推广有效的放射性皮肤炎治疗方法正在进一步推动市场扩张。因此，癌症盛行率的增加、放射治疗和治疗选择的进步以及对放射性皮肤炎管理的认识和教育的提高的综合影响预计将有助于该行业的成长。

美国放射性皮肤炎市场报告亮点

• 2023年，外用製剂销售额占75.68%。这一比例是由于广泛使用外用产品来控制放射性皮肤炎症状所致。
• 局部治疗，包括乳霜和软膏，可以直接涂布受影响的区域，立即缓解症状并降低全身副作用的风险。
• 2023年，零售药局领域占最大的销售份额。这种增长归因于可及性和便利性。零售药局是许多寻求非处方治疗放射性皮肤炎等疾病的患者的主要接触点。
• 2023年，独立放射治疗中心部门占收益占有率最大。这是由于我们专注于先进放射治疗、减少辐射暴露和提高肿瘤靶向准确性。此外，这些中心通常采取更个人化的方法，这可以提高患者满意度和重复就诊率。
• 市场参与者正在采取各种策略倡议来扩大其产品在不同地区的覆盖范围和可用性。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国放射性皮肤炎市场变数、趋势、范围

• 市场体系展望
  • 相关/附随市场展望
• 美国各种癌症的发生率
• 2024年美国各种癌症发生率和死亡率
• 2024 年美国癌症发生率预测（按州）
• 2024年美国选择放射线治疗并患有放射性皮肤炎的患者人数
• 放射性皮肤炎的程度取决于癌症类型
• 使用临床参数表征癌症诱发的放射性皮肤炎
• 放射治疗设施的类型（美国的各种癌症）
• 放射性皮肤炎治疗的平均产品成本
• 产品市场机会
• 市场动态
  • 市场推动要素分析
  • 市场限制因素分析
• 美国放射性皮肤炎市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章美国放射性皮肤炎市场：产品估算及趋势分析

• 美国放射性皮肤炎市场：产品仪表板
• 美国放射性皮肤炎市场：产品变化分析
• 2018-2030年美国放射性皮肤炎市场规模、预测与趋势分析（按产品）
• 外用
• 覆盖材料

第五章美国放射性皮肤炎市场：通路估计与趋势分析

• 美国放射性皮肤炎市场：分销通路仪表板
• 美国放射性皮肤炎市场：分销管道波动分析
• 2018-2030年美国放射性皮肤炎市场规模、预测与趋势分析（依通路）
• 医院药房
• 零售药房
• 网路药房

第六章美国放射性皮肤炎市场：设施类型的估计和趋势分析

• 美国放射性皮肤炎市场：设施类型仪表板
• 美国放射性皮肤炎市场：设施类型变化分析
• 2018-2030 年美国放射性皮肤炎市场规模、预测与趋势分析（按设施类型）
• 医院附设放射治疗中心
• 独立放射治疗中心

第七章 竞争格局

• 主要市场参与企业的最新趋势和影响分析
• 公司/竞争对手分类
• 供应商情况
  • 主要经销商及通路伙伴名单
  • Stratpharma AG
  • Smith &Nephew plc
  • Molnlycke Health Care AB
  • Derma Sciences Inc
  • Convatec Inc
  • 3M Company
  • Alliqua BioMedical
  • BMG Pharma spA

U.S. Radiodermatitis Market Growth & Trends:

The U.S. radiodermatitis market size is expected to reach USD 481.07 million by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several key factors, including the increasing prevalence of cancer, advancements in radiation therapy techniques, and the development of new treatment options for radiodermatitis are contributing to this growth. The growing burden of cancer is a significant factor driving market growth. With cancer being one of the leading causes of death worldwide, the demand for effective radiation therapy and subsequent management of radiodermatitis is growing. The high incidence of cancer types, such as breast and prostate cancers, which often require radiation therapy, is expected to boost market expansion. Moreover, the growing geriatric population, which is more susceptible to chronic diseases such as cancer, is boosting the demand for radiodermatitis treatment.

The market growth is also affected by the development of new treatment options for radiodermatitis, such as topical creams, dressings, and oral medications, which has expanded the market scope. Although these innovations offer patients more choices in managing their symptoms and potentially lead to improved quality of life & reduced healthcare costs associated with severe cases of radiodermatitis, they may also reduce the demand for traditional radiodermatitis management solutions. For instance, in April 2024, Molnlycke announced an agreement to acquire P.G.F. Industry Solutions GmbH, a prominent wound cleansing manufacturer. This acquisition is expected to help the company strengthen its position as a global leader in wound care.

Moreover, growth is also influenced by the increasing awareness and education among healthcare professionals & patients regarding the importance of managing radiodermatitis. This awareness has led to a greater emphasis on preventive measures and early intervention, which are crucial in minimizing the severity of radiodermatitis & improving patient outcomes. Collaborations between healthcare providers, researchers, and pharmaceutical companies to develop & promote effective radiodermatitis treatments further drive market expansion. Thus, the combined impact of the increasing prevalence of cancer, advancements in radiation therapy & treatment options, and the growing awareness & education about radiodermatitis management is expected to contribute to industry growth.

U.S. Radiodermatitis Market Report Highlights:

• The topical product segment accounted for a revenue share of 75.68% in 2023. This share can be attributed to the widespread use of topical products in managing the symptoms of radiodermatitis.
• Topical treatments, including creams & ointments, can be directly applied to the affected area, providing immediate relief and reducing the risk of systemic adverse effects.
• The retail pharmacies segment held the largest revenue share in 2023. This growth can be attributed to their accessibility and convenience. Retail pharmacies serve as a primary point of contact for many patients seeking over-the-counter treatments for conditions such as radiodermatitis.
• The independent radiotherapy centers segment held the largest revenue share in 2023. This is due to their focus on advanced radiotherapy treatments, reduced radiation exposure, and increased precision in tumor targeting. Moreover, these centers often have a more personalized approach, which can lead to higher patient satisfaction and repeat business.
• Market players are undertaking various strategic initiatives to enhance product reach and availability across different geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution channel
  • 1.2.3. Facility type
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. Epidemiology-based Market Analysis
  • 1.8.1. Research Scope and Assumptions
  • 1.8.2. Research Methodology and Assumptions
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Distribution channel
  • 2.2.3. Facility type
• 2.3. Competitive Insights

Chapter 3. U.S. Radiodermatitis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Related/ancillary market outlook
• 3.2. Prevalence of Different Cancer Types in the U.S.
• 3.3. Incidence and Mortality Rates of Different Cancer Types in the U.S. in 2024
• 3.4. Expected Cancer Incidence in the U.S. for 2024 (by States)
• 3.5. Number of Patients Opting for Radiation Therapy and Suffering From Radiodermatitis in the U.S. in 2024
• 3.6. Grades of Radiodermatitis for Different Cancer Types
• 3.7. Characterization of Radiodermatitis for Cancer Using Clinical Parameters
• 3.8. Facility Types for Radiation Therapy (for Different Types of Cancer in the U.S.)
• 3.9. Average Product Cost for Radiodermatitis Treatment
• 3.10. Product Market Opportunities
• 3.11. Market Dynamics
  • 3.11.1. Market driver Analysis
    • 3.11.1.1. Increasing cancer incidence
    • 3.11.1.2. Advancements in radiation therapy
  • 3.11.2. Market restraint analysis
    • 3.11.2.1. High cost of treatment
• 3.12. U.S. Radiodermatitis Market Analysis Tools
  • 3.12.1. Industry Analysis - Porter's
    • 3.12.1.1. Supplier power
    • 3.12.1.2. Buyer power
    • 3.12.1.3. Substitution threat
    • 3.12.1.4. Threat of new entrant
    • 3.12.1.5. Competitive rivalry
  • 3.12.2. PESTEL Analysis
    • 3.12.2.1. Political landscape
    • 3.12.2.2. Technological landscape
    • 3.12.2.3. Economic landscape

Chapter 4. U.S. Radiodermatitis Market: Product Estimates & Trend Analysis

• 4.1. U.S. Radiodermatitis Market: Product Dashboard
• 4.2. U.S. Radiodermatitis Market: Product Movement Analysis
• 4.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Topical
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.1. Corticosteroids
    • 4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Hydrophilic Creams
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Antibiotics
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Others
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Dressings
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.1. Hydrogel and Hydrocolloid Dressings
    • 4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.2. No Sting Barrier Films
    • 4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.3. Honey-Impregnated Gauze
    • 4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.4. Silicone-Coated Dressings
    • 4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.5. Others
    • 4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

• 5.1. U.S. Radiodermatitis Market: Distribution Channel Dashboard
• 5.2. U.S. Radiodermatitis Market: Distribution Channel Movement Analysis
• 5.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Radiodermatitis Market: Facility Type Estimates & Trend Analysis

• 6.1. U.S. Radiodermatitis Market: Facility Type Dashboard
• 6.2. U.S. Radiodermatitis Market: Facility Type Movement Analysis
• 6.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Facility Type, 2018 to 2030 (USD Million)
• 6.4. Hospital-based Radiotherapy Centers
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Independent Radiotherapy Centers
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Stratpharma AG
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Type benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Smith & Nephew plc
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Type benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Molnlycke Health Care AB
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Type benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Derma Sciences Inc
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Type benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Convatec Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Type benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. 3M Company
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Type benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Alliqua BioMedical
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Type benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. BMG Pharma spA
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Type benchmarking
    • 7.3.9.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 5-year prevalence of different cancer types in the U.S.
• Table 3 Incidence and mortality rates of different cancer types in the U.S. in 2024
• Table 4 Average product cost for radiodermatitis treatment in the U.S.
• Table 5 U.S. radiodermatitis market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)
• Table 6 U.S. radiodermatitis market revenue estimates and forecast, by facility type, 2018 - 2030 (USD Million)
• Table 7 U.S. radiodermatitis market analysis revenue estimates and forecast, by distribution channel, 2018 - 2030 (USD Million)
• Table 8 Key companies undergoing product launches.
• Table 9 Key companies undergoing partnerships & collaborations
• Table 10 Key companies undergoing initiating mergers/acquisitions.
• Table 11 Key companies undergoing other strategies.

List of Figures

• Fig. 1 U.S. radiodermatitis market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Epidemiology-based market analysis
• Fig. 8 QFD modelling for market share assessment
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Product and distribution channel)
• Fig. 11 Segment snapshot (Facility type)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 5-year prevalence of cancer in the U.S.
• Fig. 14 Leading cancer types (incidence and mortality)
• Fig. 15 Top 10 U.S. states contributing to highest cancer cases in 2024
• Fig. 16 Top 10 U.S. states contributing to breast, colon, rectum, lung and bronchus, and prostate cancer cases in 2024
• Fig. 17 Estimated patients undergoing radiation therapy and suffering from radiodermatitis in the U.S. for selected cancer types in 2024
• Fig. 18 Stage wise distribution of cancer patients receiving radiation therapies-I
• Fig. 19 Stage wise distribution of cancer patients receiving radiation therapies-II
• Fig. 20 Grade of radiodermatitis for different cancer types
• Fig. 21 Characterization of radiodermatitis for cancer using clinical parameters
• Fig. 22 Facility types for radiation therapy in the U.S.
• Fig. 23 Market opportunity in the U.S.
• Fig. 24 Market potential for topical and dressing products for radiodermatitis treatment in the U.S.
• Fig. 26 U.S. Radiodermatitis Market: Product dashboard
• Fig. 27 U.S. radiodermatitis market: Product movement analysis
• Fig. 28 U.S. Radiodermatitis facility type dashboard
• Fig. 29 U.S. radiodermatitis market: Facility type movement analysis
• Fig. 30 U.S. Radiodermatitis distribution channel dashboard
• Fig. 31 U.S. radiodermatitis market: Distribution channel movement analysis
• Fig. 32 Key company categorization
• Fig. 33 Company market position analysis
• Fig. 34 Strategic framework